default author photo

Federica Morano

Fondazione IRCCS Istituto Nazionale dei Tumori

Via Giacomo Venezian, 1

Milano MI, 20133

Italy

SCHOLARLY PAPERS

1

DOWNLOADS

54

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

First-Line Panitumumab Plus FOLFOX-4 Followed by Maintenance Therapy with Single-Agent Panitumumab or Panitumumab Plus 5-FU/LV in Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Valentino Study

Number of pages: 107 Posted: 05 Oct 2018
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pisa - Department of Oncology, Humanitas University - Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Grande Ospedale Metropolitano Niguarda, University of Turin, Azienda Ospedaliero-Universitaria Careggi, Ente Ospedaliero Ospedali Galliera, University of Messina, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Humanitas University, Università degli Studi di Genova, Fondazione Poliambulanza, University of Messina, University of Messina, Azienda Socio Sanitaria Territoriale Lariana, Azienda Socio Sanitaria Territoriale Bergamo Ovest, Azienda Ospedaliera San Gerardo, Ospedale Antonio Perrino, University of Pisa - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department
Downloads 54 (1,041,696)

Abstract:

Loading...

colorectal cancer; maintenance treatment; panitumumab; RAS wild-type; randomised trial